SIGLEC15 and pancreatic ductal adenocarcinoma: In pancreatic ductal adenocarcinoma, SIGLEC15 has been identified as a tumor-associated macrophage-associated immune checkpoint that polarizes M2-type macrophages and promotes tumor growth (Li et al., 2022).